Delamanid (OPC-67683)

Delamanid, also known as OPC-67683, is a drug for the treatment of multi-drug-resistant tuberculosis. It works by blocking the synthesis of mycolic acids in Mycobacterium tuberculosis, the organism which causes tuberculosis, thus destabilising its cell wall. The drug is approved in the EU. Delamanid inhibits the synthesis of mycolic acids, crucial component of the cell wall of the Mycobacterium tuberculosis complex. Delamanid is insoluble in water and its activity was proven in several in vitro and in vivo studies. Its bactericidal activity was demonstrated in individuals with drug-susceptible and drug-resistant tuberculosis (MDR- and XDR-TB).

Product information

CAS Number: 681492-22-8

Molecular Weight: 534.48

Formula: C25H25F3N4O6

Synonym:

OPC-67683

Deltyba

OPC 67683

OPC67683

Delamanid

trade name Deltyba

Chemical Name: (2R)-2-Methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole

Smiles: C[C@]1(COC2C=CC(=CC=2)N2CCC(CC2)OC2C=CC(=CC=2)OC(F)(F)F)CN2C=C(N=C2O1)[N+]([O-])=O

InChiKey: XDAOLTSRNUSPPH-XMMPIXPASA-N

InChi: InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

Delamanid inhibits the synthesisi of mucolic acids, cruciala component of the cell wall of the Mycobacterium tuberculosis complex. Delamanid shows more potent antibacterial activity against drug-susceptible and drug-resistant strains of M. tuberculosis. Delamanid do not affect rifampin, pyrazinamide, and isoniazid exposure; the ethambutol AUCτ and Cmax values are about 25% higher with delamanid coadministration.

In Vivo:

Delamanid (orally administration; 30 mg/kg; 5 days) results in sterile cures in a mouse model of VL.

References:

1. Rustomjee R, Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis. Infect Drug Resist. 2015 Oct 29;8:359-366. eCollection 2015. Review. PubMed PMID: 26604805; PubMed Central PMCID: PMC4631416.
2. Brigden G, Hewison C, Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect Drug Resist. 2015 Oct 30;8:367-378. eCollection 2015. Review. PubMed PMID: 26586956; PubMed Central PMCID: PMC4634826.

Products are for research use only. Not for human use.